| LinkedIn
Reach out to members who know this skillFind and connect to LinkedIn members who know Phases ILooking to hire?Get unbeatable access to people who know Phases I with LinkedIn Jobs.Past experienceCompany placeholder imageDividend Input Specialist at COMPUTERSHARE ServicesCompany placeholder imageDividend Input Specialist at Computershare ServicesCompany placeholder imageStaff Analyst at HARRIS TRUST & SAVINGS BANKCompany placeholder imageShareholder Representative at HARRIS TRUST & SAVINGS BANKEducationCompany placeholder imageJones CommericalSummaryMARCIA E. DURAN
17509 Gilbert Dr.
(630) 730-1976
Lockport, Il 60441
I have over 30 years of all phases of office...show aboveshow belowCompany placeholder imageFreelance CRA at .Company placeholder imageCRA/lead-CRA at Clinical Monitoring & Trial Consultingshow aboveshow belowCompany placeholder imageI was a forman at mc bride and also worked service. Just a journeyman electrician at Mc Bride at Burg Electrict out of escondido, also McBride Electric in San Diego and 4 or 5 other contratorsCompany placeholder imageLead Electrician at Grossmont CollegeEducationSan Diego State Universityshow aboveshow belowPerson placeholder imageCancer Research UK Ambassador at Cancer Research UKCompany placeholder imageEntrepreneur at Self EmployedPast experienceQA Auditor at Worldwide Clinical TrialsQuality Control Specialist at Worldwide Clinical TrialsSubmission Certificate Coordinator at GSKMedical Labelling Specialist at PfizerEducationUniversity of BedfordshireSummaryAn experienced Clinical Specialist who has worked in Regulatory Affairs since 2009 with training in GLP, GVP, GCP and GMP
regulatory...show aboveshow belowVice President, Hematology and CART, USCDMA at NovartisPast experienceVice President, Global Clinical Research, Immuno-Oncology at Bristol-Myers SquibbClinical Head, Translational Clinical Oncology at NovartisHead, Oncology Translational Medicine Japan at NovartisClinical Program Leader at NovartisEducationUniversity of BristolCompany placeholder imageRepton Schoolshow aboveshow belowJoin our Phases I community on LinkedInChargée de projets at WSP (previously GENIVAR)Instructrice de yoga certifiée at Les YMCA du QuébecPast experienceChargée de projets en environnement at ORTAM GROUPE Inc.Analyste en environnement at TPSGCStagiaire en évaluations environnementales et milieu marin at TPSGCCompany placeholder imageAnimatrice d'institutions scientifiques at Jardin botanique de MontréalEducationUniversité du Québec à MontréalMcGill UniversityCompany placeholder imagePSNMshow aboveshow belowPerson placeholder imageClinical Lead,
at Bristol-Myers SquibbPast experienceDirector, Oncology Clinical Research at The Janssen Pharmaceutical Companies of Johnson & JohnsonOncology Study Physician, Global Clinical Development at Bayer HealthCare PharmaceuticalsEducationThe Johns Hopkins UniversityCompany placeholder imageUniversity of Washington Medical CenterSummaryA physician scientist and leader, focusing on Oncology Clinical Development in Pharmaceutical/Biotech companies. Experiences with both Late...show aboveshow belowPerson placeholder imageshow aboveshow belowCompany placeholder imageControl Valve Manager at Soon To Be AnnouncedPast experienceControl Valve Tech at Setpoint Integrated Solutions, Inc. (Formerly DMC Carter Chambers, Inc.)Company placeholder imageOwner/Tech at Bob's Auto RepairEducationLamar State College-Port ArthurTexas State Technical College WacoSummaryI believe in providing an honest days work for an honest days pay. I am a 100% dependable employee. I feel as though an employees...show aboveshow belowPerson placeholder imageCompany placeholder imageChargé de projets principal
Caractérisation environnementale
Principal Project Manager
(C-NRPP) at Amec Foster Wheeler - Environment and InfrastructuresChargé de projet Senior Project Manager - Environnement / Radon at Amec Foster WheelerPast experienceChargé de projet en Environnement - Senior Project Manager Soil Characterization at exp Global Inc.Company placeholder imageChargé de projet Environnement at D&G Enviro-Group Inc.Company placeholder imageGéologue junior at OmégalphaEducationUniversité du Québec à Montréal / UQAMConcordia UniversitySummaryDepuis l’obtention de mon dipl?me universitaire en 2000, j'ai oeuvré dans des firmes de consultation et d’ingénierie et acquis de...show aboveshow belowTMF Operations Lead at PfizerTrial Master File (TMF) Business Support and CAPA Management Lead at PfizerPast experienceTrial Master File (TMF) Alliance Partner (AP) Transition Lead at PfizerCompany placeholder imageAssociate Director, Business Operations Lead at Pfizer Pharmaceuticals IncSenior Associate, Regulatory Operations at PfizerSupply Chain Coordinator, Pharmaceutical Sciences at PfizerEducationUniversity of New HavenUniversity of New HavenSummaryPersonable business professional with advanced college degrees and a successful 29-plus years career in the pharmaceutical industry with...show aboveshow belowDirector, Strategic Planning and Clinical Operations at Regeneron Pharmaceuticals, Inc.Director, Clinical Trial Management at Regeneron Pharmaceuticals, Inc.Past experienceAssociate Director, Clinical Trial Management at Regeneron PharmaceuticalsAssociate Director, Clinical Operations at Purdue PharmaDirector, Clinical Operations at Roche PharmaceuticalsGlobal Studies Leader at Roche PharmaceuticalsEducationRutgers, The State University of New Jersey-New Brunswickshow aboveshow belowCompany placeholder imageAssociate Director, Clinical Operations, Medical at Actelion Pharmaceuticals US, Inc.show aboveshow belowCompany placeholder imageLibero professionista, docente, direttore didattico at CPO FULFORDPast experienceCompany placeholder imageDOCENTE OSTEOPATIA STRUTTURALE/VERTEBRALE at CERDOCompany placeholder imageIFC/ODA/CERDO at PAVIA/ROMA/MILANOEducationCompany placeholder imageC.E.R.D.O./ US UNIVERSITYCompany placeholder imageUNIPSICompany placeholder imageUniversità degli Studi di Pavia / University of Pavia/University of Verona/ U.S University/CerdoSummaryDiploma Osteopatia CERDO,Laurea dottorale in Osteopatia (US, Missouri) e formazione Biodinamica con J.S. Jealous DO (US,Oregon), laurea in...show aboveshow belowPerson placeholder imageDSM Franchise Head - Oncology (Hematology & Rare Diseases) at NovartisPast experienceDemand Planner at NovartisTeam Head - General Medicine India at NovartisTrial Manager at NovartisCompany Manager - Team Lead at NovartisEducationIndian Institute of Management, BangaloreCranfield UniversityCompany placeholder imageInstitute of Clinical Research (India), MumbaiSummaryKey Responsibilities:
- Widen collaborative relationships with investigative sites and clients
- Negotiate budgets for trial sites and...show aboveshow belowCEO/CSO Xceed Clinical at Xceed Clinical Research Inc.Company placeholder imageMedical Director and Principal Investigator at Kids ClinicPast experienceCompany placeholder imageSenior Medical Director, Principal Investigator at Cetero Research/ PRACS InstituteCompany placeholder imageCEO/CSO at Qualia Clinical ServicesStaff Division of Clinical Pharmacology and Emergency Medicine at The Hospital for Sick ChildrenEducationCompany placeholder imageUniversity of TorontoCompany placeholder imageKhyber Medical Collegeshow aboveshow belowPerson placeholder imageCountry Study Specialist at RochePast experienceFreelance EU Lead CRA at ICON plcLead Clinical Research Associate at Covance- Co-source contracted with SanofiIn-house CRA II at PRA InternationalClinical Research Associate at Quintiles Transnational- Global Functional Resourcing contracted with AmgenEducationCompany placeholder imageCentre for Advancement in Health SciencesCompany placeholder imageDapoli Homoeopathic Medical CollegeCompany placeholder imageWilson CollegeSummaryGoals: To achieve a position of accountability in an organization of excellent concern, which would provide challenging work environment...show aboveshow belowDirecteur développement des affaires (mines) et géologue (mine et environnement) at ARCADISPast experienceCompany placeholder imageSpécialiste en environnement at StantecEducationUniversité du Québec à Montréal / UQAMSummaryM. Stéphane Pelletier possède plus de 12 années d’expérience dans le domaine de l’environnement, ainsi que dans le domaine minier.
Au...show aboveshow belowBusiness Development Manager at Schneider ElectricPast experienceIndustry & Process Automation Manager at Schneider ElectricIV&V Group Head at Schneider ElectricIV&V Group Head at Invensys - Acquired by Schneider ElectricPrincipal Engineer at Invensys - Acquired by Schneider ElectricEducationThe American University in CairoCompany placeholder imageInstitute of Aviation Engineering and Technologyshow aboveshow belowPerson placeholder imageClinical Operations - GCP and Clinical Compliance at Teva PharmaceuticalsPast experienceProject Manager Clinical Research at CEPHALON EUROPECompany placeholder imageGroup Leader Clinical Operation at CEPHALON FRANCECompany placeholder imageSenior Clinical Research Associate at Laboratoire Louis LAFONCompany placeholder imageClinical Research Associate at D R C - H?pital Saint Louis Paris (AP-HP)EducationCompany placeholder imageRené Descartes Pharmacy University - Paris VCompany placeholder imagePierre & Marie CURIE University - Paris VICompany placeholder imageUniversity Paris VIISummaryPROFESSIONAL EXPERTISE AND EXPERIENCE
GCP AUDIT - CLINICAL QUALITY COMPLIANCE
o Vendors’ Audit : CROs,
Phase 1 units and investigational...show aboveshow belowShow moreShow lessPopular articles for this topicDaily news and insights from real experts on LinkedInShow moreShow less& 52,949 Results
Supplier Location:
Supplier Types:
Relevancy Transaction Level Response Rate
Minimum Order:
1 Piece (Min. Order)
1 Unit (Min. Order)
10 Pieces (Min. Order)
US $120-450
1 Set (Min. Order)
1 Piece (Min. Order)
US $100-520
1 Set (Min. Order)
100 Sets (Min. Order)
1 Piece (Min. Order)
1 Set (Min. Order)
US $169-179
1 Piece (Min. Order)
US $100-120
1 Piece (Min. Order)
US $625.0-645.0
1 Piece (Min. Order)
US $0.2-1.5
1 Piece (Min. Order)
US $1-1000
1 Unit (Min. Order)
US $130-200
10 Units (Min. Order)
/ Piece | Buy Now
1 Piece (Min. Order)
US $180-220
10 Pieces (Min. Order)
1 Set (Min. Order)
1 Piece (Min. Order)
1 Piece (Min. Order)
US $107-430
30 Pieces (Min. Order)
US $518-676
1 Set (Min. Order)
US $150-200
10 Units (Min. Order)
US $64-1288
6 Units (Min. Order)
US $210-211
100 Pieces (Min. Order)
US $615-950
2 Pieces (Min. Order)
US $500-900
1 Unit (Min. Order)
US $10-200
5 Pieces (Min. Order)
US $0.01-100
50 Pieces (Min. Order)
US $0.1-1.5
200 Pieces (Min. Order)
US $230-270
1 Piece (Min. Order)
US $40-78.43
10 Sets (Min. Order)
1 Piece (Min. Order)
10 Sets (Min. Order)
US $0.85-1.15
1200 Watts (Min. Order)
1 Piece (Min. Order)
US $286-320
1 Piece (Min. Order)
1 Set (Min. Order)
Go to Page
Buying Request Hub
Haven't found the right supplier yet ? Let matching verified suppliers find you.
Do you want to show power line phases or other products of your own company?
Related Category
Product Features
Output Type
Output Power
Certification
Sample OrderNEW
Minimum Order:
Supplier Features
Supplier by Area
Suppliers by Country/Region
Supplier Types
Top 3 Markets
Total Revenue
Mgnt Certification
Recommendation for you
related suppliers
related Guide
related from other country
ensearchweb皮膚·皮膚組織感染疾病(SSSI)治療藥物:開發平台評估與市場預測
Skin and Skin Structure Infections (SSSI) Therapeutics - Pipeline Assessment and Market Forecasts to 2019
出版日期: 日
內容資訊: 英文 79 Pages
本報告已在日停止出版
全球皮膚、皮膚組織感疾病治療藥的市場規模，從2006年的17億410萬美金，擴大到2011年的24億1950萬美金。一般預測到2019年將擴大到25億7310萬美金的規模。年的年平均(CAGR）市場成長率為7.3%，一般推測預定年的成長率為0.8%。
本報告提供皮膚·皮膚組織感染疾病(SSSI)治療法研究及開發的最新趨勢調查，進行相關的市場預測，疾病的概要與應對法，全球及主要7個國家（美國·EU5個國家·日本)的市場規模測量與預測(過去6年·今後10年分)，競爭結構、臨床實驗進行狀況相關開發平台的評估，今後的市場趨勢及企業策略相關的策略性考察等等資訊彙整，為您概述為以下內容。
第1章 目錄
第2章 皮膚·皮膚組織感染疾病:簡介
治療·管理模式
本報告概要
第3章 市場特徵
市場規模實際成果值·預測值:全球(總計16年分)
市場規模實際成果值·預測值:美國(總計16年分)
市場規模實際成果值·預測值:法國(總計16年分)
市場規模實際成果值·預測值:德國(總計16年分)
市場規模實際成果值·預測值:西班牙(總計16年分)
市場規模實際成果值·預測值:義大利(總計16年分)
市場規模實際成果值·預測值:英國(總計16年分)
市場規模實際成果值·預測值:日本(總計16年分)
市場促進·阻礙因素
市場機會及未滿足需求
主要的結論
第4章 競爭力評估
競爭企業的策略性評估
主要的市售產品簡介
Vancomycin
Zyvox (linezolid)
Cubicin (daptomycin)
Vibativ (telavancin)
Tygacil (tigecycline)
Avelox (Moxifloxacin hydrochloride)
Zosyn (piperacillin/tazobactam)
Teflaro (Ceftaroline)
主要的市售產品比較
主要的結論
第5章 開發平台評估
策略性開發平台評估
各開發階段的開發平台評估
階段III開發平台
階段II開發平台
階段I開發平台
前臨床開發平台
藥物發明開發平台
各行動機制的平台
技術趨勢分析架構
臨床實驗中的最有潛力的藥物
最有潛力的藥物簡介
Torezolid phosphate (TR-701, DA-7218)
美國食品醫藥品局(FDA)審查到最後階段的分子
主要的結論
第6章 臨床實驗藍圖
各國/不同地區的臨床實驗數(美國，EU5個國家，日本)
各階段臨床實驗數
各篩檢階段臨床實驗數
有潛力的贊助商
參與臨床實驗的企業前十大企業的概略
第7章 策略性評估
今後的影響市場的主要事項
今後的市場競爭的預測
第8章 未來市場參與企業
武田藥品工業
Basilea Pharmaceuticals
Forest Laboratories
Novartis AG.
Trius Therapeutics, Inc.
The Medicines Company
Biosynexus Incorporated
AstraZeneca PLC
GlaxoSmithKline plc
e-Therapeutics plc
Rib-X Pharmaceuticals, Inc
主要的結論
第9章 專利·合作交易
第10章 附錄
Product Code: GDHC342PRTAbstract
Skin and Skin Structure Infections (SSSI) Therapeutics - Pipeline Assessment and Market Forecasts to 2019
GlobalData, the industry analysis specialist, has released its new report, "Skin and Skin Structure Infections (SSSI) Therapeutics - Pipeline Assessment and Market Forecasts to 2019". The report is an essential source of information and analysis on the global Skin and Skin Structure Infections Therapeutics market. The report identifies the key trends shaping and driving the global Skin and Skin Structure Infections Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Skin and Skin Structure Infections Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.
The report provides information on the key drivers and challenges of the Skin and Skin Structure Infections Therapeutics market. Its scope includes -
Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Skin and Skin Structure Infections Therapeutics market revenues data from 2006 to 2011, forecast for eight years to 2019.
Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
Analysis of the current and future competition in the seven key countries Skin and Skin Structure Infections Therapeutics market.
Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Skin and Skin Structure Infections Therapeutics market.
Analysis of key recent licensing and partnership agreements in Skin and Skin Structure Infections Therapeutics market
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
Develop business strategies by understanding the trends shaping and driving the global Skin and Skin Structure Infections Therapeutics market.
Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Skin and Skin Structure Infections Therapeutics market in future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
What's the next big thing in the global Skin and Skin Structure Infections Therapeutics market landscape? - Identify, understand and capitalize.
1 Table of Contents
1 Table of Contents 3
1.1 List of Tables 5
1.2 List of Figures 6
2 Skin and Skin Structure Infections Therapeutics - Introduction 7
2.1 Overview 7
2.2 Pathophysiology 7
2.3 Epidemiology 7
2.4 Etiology 8
2.5 Symptoms 8
2.6 Diagnosis 8
2.7 Treatment and Management Pattern 9
2.8 GlobalData Report Guidance 12
3 Skin and Skin Structure Infections Therapeutics - Market Characterization 13
3.1 Skin and Skin Structure Infections Therapeutics Global Market Size () 13
3.2 Skin and Skin Structure Infections Therapeutics Global Market Forecast () 14
3.3 Skin and Skin Structure Infections Therapeutics Market () -
3.4 Skin and Skin Structure Infections Therapeutics Market Forecast () - The US 16
3.5 Skin and Skin Structure Infections Therapeutics Market () - France 17
3.6 Skin and Skin Structure Infections Therapeutics Market Forecast () - France 18
3.7 Skin and Skin Structure Infections Therapeutics Market () - Germany 19
3.8 Skin and Skin Structure Infections Therapeutics Market Forecast () - Germany 20
3.9 Skin and Skin Structure Infections Therapeutics Market () - Spain 21
3.10 Skin and Skin Structure Infections Therapeutics Market Forecast () - Spain 22
3.11 Skin and Skin Structure Infections Therapeutics Market () - Italy 23
3.12 Skin and Skin Structure Infections Therapeutics Market Forecast () - Italy 24
3.13 Skin and Skin Structure Infections Therapeutics Market () - The UK 25
3.14 Skin and Skin Structure Infections Therapeutics Market Forecast () - The UK 26
3.15 Skin and Skin Structure Infections Therapeutics Market () - Japan 27
3.16 Skin and Skin Structure Infections Therapeutics Market Forecast () - Japan 28
3.17 Drivers and Barriers for the Skin and Skin Structure Infections Therapeutics Market 29
3.17.1 Skin and Skin Structure Infections Therapeutics Market Drivers 29
3.17.2 Skin and Skin Structure Infections Therapeutics Market Barriers 29
3.18 Opportunity and Unmet Need 30
3.19 Key Takeaway 31
4 Skin and Skin Structure Infections Therapeutics - Competitive Assessment 32
4.1 Overview 32
4.2 Strategic Competitor Assessment 32
4.3 Product Profiles of the Major Market Products in the Skin and Skin Structure Infections Therapeutics Market 33
4.3.1 Vancomycin 33
4.3.2 Zyvox (linezolid) 34
4.3.3 Cubicin (daptomycin) 35
4.3.4 Vibativ (telavancin) 36
4.3.5 Tygacil (tigecycline) 37
4.3.6 Avelox (Moxifloxacin hydrochloride) 38
4.3.7 Zosyn (piperacillin/tazobactam) 39
4.3.8 Teflaro (Ceftaroline) 39
4.4 Skin and Skin Structure Infections Therapeutics - Comparison of Major Marketed Products 41
4.5 Key Takeaway 41
5 Skin and Skin Structure Infections Therapeutics - Pipeline Assessment 42
5.1 Overview 42
5.2 Strategic Pipeline Assessment 42
5.3 Skin and Skin Structure Infections Therapeutics Market - Pipeline Assessment by Phase of Development 42
5.3.1 Skin and Skin Structure Infections Therapeutics Market - Phase III Pipeline 42
5.3.2 Skin and Skin Structure Infections Therapeutics Market - Phase II Pipeline 43
5.3.3 Skin and Skin Structure Infections Therapeutics Market - Phase I Clinical Pipeline 43
5.3.4 Skin and Skin Structure Infections Therapeutics Market - Preclinical Pipeline 44
5.3.5 Skin and Skin Structure Infections Therapeutics Market - Discovery Pipeline 45
5.4 Skin and Skin Structure Infections Therapeutics - Pipeline by Mechanism of Action 46
5.5 Technology Trends Analytical Framework 47
5.6 Skin and Skin Structure Infections Therapeutics Market - Most Promising Drugs under Clinical Development 48
5.7 Most Promising Drug Profiles 49
5.7.1 Torezolid phosphate (TR-701, DA-7218) 49
5.8 Late Stage Molecules under FDA Review 50
5.9 Key Takeaway 51
6 Skin and Skin Structure Infections Therapeutics - Clinical Trials Mapping 52
6.1 Clinical Trials by Region/Country (US, EU5 and Japan) 52
6.2 Clinical Trials by Phase of Clinical Development 53
6.3 Clinical Trials by Trial Status 54
6.4 Prominent Sponsors 55
6.5 Brief Profiles of Top Ten Companies Participating in Therapeutics Clinical Trials 56
7 Skin and Skin Structure Infections Therapeutics - Strategic Assessment 57
7.1 Key Events Impacting the Future Market 57
7.2 Future Market Competition Scenario 58
8 Skin and Skin Structure Infections Therapeutics - Future Players 59
8.1 Introduction 59
8.2 Company Profiles 59
8.2.1 Takeda Pharmaceutical Company Limited 59
8.2.2 Basilea Pharmaceuticals 61
8.2.3 Forest Laboratories 61
8.2.4 Novartis AG. 63
8.2.5 Trius Therapeutics, Inc. 65
8.2.6 The Medicines Company 65
8.2.7 Biosynexus Incorporated 67
8.2.8 AstraZeneca PLC 67
8.2.9 GlaxoSmithKline plc 69
8.2.10 e-Therapeutics plc 70
8.2.11 Rib-X Pharmaceuticals, Inc 71
8.2.12 Key Takeaway 72
9 Skin and Skin Structure Infections Therapeutics - Licensing & Partnership Deals 73
10 Skin and Skin Structure Infections Therapeutics - Appendix 74
10.1 Market Definitions 74
10.2 Acronyms 74
10.3 Methodology 75
10.3.1 Coverage 76
10.3.2 Secondary Research 76
10.3.3 Forecasting 76
10.3.4 Primary Research 78
10.3.5 Expert Panel Validation 79
10.4 Contact Us 79
10.5 Disclaimer 79
10.6 Bibliography 79
List of Tables
1.1 List of Tables
Skin and Skin Structure Infections Therapeutics Market, Global, Revenue ($m),
Skin and Skin Structure Infections Therapeutics Market, Global, Forecast ($m),
Skin and Skin Structure Infections Therapeutics Market, The US, Revenue ($m),
Skin and Skin Structure Infections Therapeutics, Major Market, The US, Forecast ($m),
Table 5: Skin and Skin Structure Infections Therapeutics, France, Revenue ($m),
Skin and Skin Structure Infections Therapeutics Market, France, Forecast ($m),
Table 7: Skin and Skin Structure Infections Therapeutics, Germany, Revenue ($m),
Skin and Skin Structure Infections Therapeutics Market, Germany, Forecast ($m),
Table 9: Skin and Skin Structure Infections Therapeutics, Spain, Revenue ($m),
Table 10: Skin and Skin Structure Infections Therapeutics Market, Spain, Forecast ($m),
Table 11: Skin and Skin Structure Infections Therapeutics, Italy, Revenue ($m),
Table 12: Skin and Skin Structure Infections Therapeutics Market, Italy, Forecast ($m),
Table 13: Skin and Skin Structure Infections Therapeutics, The UK, Revenue ($m),
Table 14: Skin and Skin Structure Infections Therapeutics, Major Market, The UK, Forecast ($m),
Table 15: Skin and Skin Structure Infections Therapeutics, Japan, Revenue ($m),
Table 16: Skin and Skin Structure Infections Therapeutics, Major Market, Japan, Forecast ($m),
Table 17: Comparison of Major Marketed Products Comparison in Skin and Skin Structure Infections Therapeutics Market, 2011 41
Table 18: Skin and Skin Structure Infections Therapeutics - Phase III Pipeline, 2011 42
Table 19: Skin and Skin Structure Infections Therapeutics - Phase II Pipeline, 2011 43
Table 20: Skin and Skin Structure Infections Therapeutics - Phase I Pipeline, 2011 43
Table 21: Skin and Skin Structure Infections Therapeutics - Preclinical Pipeline, 2011 44
Table 22: Skin and Skin Structure Infections Therapeutics - Discovery Pipeline, 2011 45
Table 23: Skin and Skin Structure Infections Therapeutics Market - Most Promising Drugs Under Clinical Development, 2011 48
Table 24: Comparison of linezolid and torezolid 50
Table 25: Development Status of Ceftobiprole 50
Table 26: Development status of Dalbavancin 51
Table 27: Development Status of Iclaprim 51
Table 28: Skin and Skin Structure Infections Therapeutics - Clinical Trials by Country, 2011 52
Table 29: Skin and Skin Structure Infections Therapeutics, Major Markets - Clinical Trials by Phase, 2011 53
Table 30: Skin and Skin Structure Infections Therapeutics, Major Markets, Clinical Trials by Development Status, 2011 54
Table 31: Skin and Skin Structure Infections Therapeutics, Major Markets, Prominent Sponsors, 2011 55
Table 32: Skin and Skin Structure Infections Therapeutics Market, Global, Clinical Trials by Lead Sponsors, 2011 56
Table 33: Takeda Pipeline Products 2011 60
Table 34: Basilea Pipeline Products 2011 61
Table 35: Forest Pipeline Products 2011 63
Table 36: Pipeline Molecules 2011 64
Table 37: The Medicine Company Pipeline Products 2011 65
Table 38: The Medicine Company Pipeline Products 2011 66
Table 39: AstraZeneca Pipeline Products 2011 68
Table 40: GlaxoSmithKline Pipeline Products 2011 70
Table 41: e-Therapeutics Pipeline Products 2011 71
Table 42: GlaxoSmithKline Pipeline Products 2011 72
Table 43: Licensing and Partnership Deals 73
List of Figures
1.2 List of Figures
Figure 1: Treatment and Management Pattern for Inpatients and Outpatients SSSI 11
Figure 2: Treatment and Management Pattern for SSSI 11
Skin and Skin Structure Infections Therapeutics Market, Global, Revenue ($m),
Skin and Skin Structure Infections Therapeutics Market, Global, Forecast ($m),
Skin and Skin Structure Infections Therapeutics Market, The US, Revenue ($m),
Skin and Skin Structure Infections Therapeutics Market, The US, Forecast ($m),
Skin and Skin Structure Infections Therapeutics Market, France, Revenue ($m),
Skin and Skin Structure Infections Therapeutics Market, France, Forecast ($m),
Figure 9: Skin and Skin Structure Infections Therapeutics Market, Germany, Revenue ($m),
Figure 10: Skin and Skin Structure Infections Therapeutics Market, Germany, Forecast ($m),
Figure 11: Skin and Skin Structure Infections Therapeutics Market, Spain, Revenue ($m),
Figure 12: Skin and Skin Structure Infections Therapeutics Market, Spain, Forecast ($m),
Figure 13: Skin and Skin Structure Infections Therapeutics Market, Italy, Revenue ($m),
Figure 14:
Skin and Skin Structure Infections Therapeutics Market, Italy, Forecast ($m),
Figure 15: Skin and Skin Structure Infections Therapeutics Market, The UK, Revenue ($m),
Figure 16: Skin and Skin Structure Infections Therapeutics Market, The UK, Forecast ($m),
Figure 17:
Skin and Skin Structure Infections Therapeutics Market, Japan, Revenue ($m),
Figure 18: Skin and Skin Structure Infections Therapeutics Market, Japan, Forecast ($m),
Figure 19:
Opportunity and Unmet Need in the Skin and Skin Structure Infections Therapeutics Market 31
Figure 20: Strategic Competitor Assessment 33
Figure 21: Skin and Skin Structure Infections Therapeutics - Clinical Pipeline by Mechanism of Action, 2011 46
Figure 22:
Skin and Skin Structure Infections Therapeutics Market - Pipeline by Phase of Development, 2011 47
Figure 23: Technology Trends Analytics Framework, 2011 47
Figure 24: Technology Trends Analytics Framework - Description, 2011 48
Figure 25: Skin and Skin Structure Infections Therapeutics - Clinical Trials by Country, 2011 52
Figure 26: Skin and Skin Structure Infections Therapeutics, Major Markets - Clinical Trials by Phase, 2011 53
Figure 27:
Skin and Skin Structure Infections Therapeutics, Major Markets, Clinical Trials by Development Status, 2011 54
Figure 28:
Skin and Skin Structure Infections Therapeutics, Major Markets, Prominent Sponsors, 2011 55
Figure 29:
Skin and Skin Structure Infections Therapeutics, Major Markets, Clinical Trials of Top 10 Companies by Phase, 2011 56
Figure 30: Skin and Skin Structure Infections Therapeutics Market, Drivers and Restraints 2011 57
Figure 31:
Implications for Future Market Competition in the Skin and Skin Structure Infections Therapeutics Market, 2011 58
Figure 32:
Skin and Skin Structure Infections Therapeutics Market - Clinical Pipeline by Company, 2011 59
Figure 33: GlobalData Market Forecasting Model 78